The CFO’s Guide to Maximizing 340B ROI
For CFOs, the 340B program is about more than compliance — it’s about revenue strategy. In today’s healthcare landscape, with rising drug costs and tightening margins, the ability to capture every eligible claim can mean the difference between breaking even and reinvesting in patient care.
Why Revenue Transparency Matters
According to the American Hospital Association, hospitals spent more than $115 billion on prescription drugs in 2023. For many organizations, 340B savings represent one of the only ways to offset these costs. Yet without clear visibility, CFOs risk leaving significant revenue unclaimed.
The Government Accountability Office (GAO) has found that incomplete oversight and limited data access reduce program benefits. Without real-time transparency, CFOs can’t accurately forecast financial impact or ensure compliance.
The Financial Impact of Missed Claims
Missed claims are more than compliance risks — they are direct revenue losses. Studies highlighted by Drug Channels Institute show that TPAs can miss up to 20% of eligible claims. For a mid-sized health system, that can equal hundreds of thousands — or even millions — in lost savings annually.
Example: A large regional hospital identified $1.2 million in additional savings over a 12-month period after implementing Halo340B’s Second Check Engine alongside their TPA.
Halo340B puts CFOs in control with:
Real-Time ROI Dashboards: Track savings, missed claims, and compliance performance instantly.
Independent Claim Validation: Recover up to 20% more eligible claims missed by TPAs.
Audit-Ready Reports: Ensure HRSA compliance without the administrative burden.
Financial Forecasting Tools: Project future savings to guide strategic decisions.
With these tools, CFOs can move from reactive compliance management to proactive revenue strategy.
